# NVE Corp: financial statements, quarterly

NVEC · Nasdaq · CIK 724910 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/nvec.md) · [Financials](/companies/nvec/financials.md) · [Filings](/companies/nvec/filings.md) · [Insiders](/companies/nvec/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvec/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | Q2 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.8](/filings/0001376474-25-000101.md) | [7.1 d](/filings/0001376474-25-000437.md) | [6.8](/filings/0001376474-25-000658.md) | [6.8](/filings/0001376474-25-000857.md) | [5.1](/filings/0001376474-26-000059.md) | [7.3 d](/filings/0001376474-26-000348.md) | [6.1](/filings/0001376474-26-000514.md) | [6.3](/filings/0001376474-26-000664.md) | [6.2](/filings/0001376474-26-000059.md) | [7.7 d](/filings/0001376474-26-000348.md) | [11.0](/filings/0001376474-26-000514.md) | [5.8](/filings/0001376474-26-000664.md) |
| Cost of revenue | $m | [1.4](/filings/0001376474-25-000101.md) | [1.7 d](/filings/0001376474-25-000437.md) | [1.0](/filings/0001376474-25-000658.md) | [0.9](/filings/0001376474-25-000857.md) | [0.8](/filings/0001376474-26-000059.md) | [1.5 d](/filings/0001376474-26-000348.md) | [1.2](/filings/0001376474-26-000514.md) | [1.4](/filings/0001376474-26-000664.md) | [1.3](/filings/0001376474-26-000059.md) | [1.7 d](/filings/0001376474-26-000348.md) | [2.1](/filings/0001376474-26-000514.md) | [1.3](/filings/0001376474-26-000664.md) |
| Gross profit | $m | [5.4](/filings/0001376474-25-000101.md) | [5.3 d](/filings/0001376474-25-000437.md) | [5.8](/filings/0001376474-25-000658.md) | [5.8](/filings/0001376474-25-000857.md) | [4.3](/filings/0001376474-26-000059.md) | [5.8 d](/filings/0001376474-26-000348.md) | [4.9](/filings/0001376474-26-000514.md) | [5.0](/filings/0001376474-26-000664.md) | [4.9](/filings/0001376474-26-000059.md) | [5.9 d](/filings/0001376474-26-000348.md) | [9.0](/filings/0001376474-26-000514.md) | [4.6](/filings/0001376474-26-000664.md) |
| Research and development | $m | [0.5](/filings/0001376474-25-000101.md) | [0.8 d](/filings/0001376474-25-000437.md) | [0.9](/filings/0001376474-25-000658.md) | [0.8](/filings/0001376474-25-000857.md) | [0.9](/filings/0001376474-26-000059.md) | [1.0 d](/filings/0001376474-26-000348.md) | [0.7](/filings/0001376474-26-000514.md) | [0.9](/filings/0001376474-26-000664.md) | [0.8](/filings/0001376474-26-000059.md) | [0.8 d](/filings/0001376474-26-000348.md) | [0.9](/filings/0001376474-26-000514.md) | [0.7](/filings/0001376474-26-000664.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001376474-26-000664.md) | not reported | not reported | not reported | [0.6](/filings/0001376474-26-000664.md) |
| Operating income | $m | [4.5](/filings/0001376474-25-000101.md) | [4.1 d](/filings/0001376474-25-000437.md) | [4.4](/filings/0001376474-25-000658.md) | [4.4](/filings/0001376474-25-000857.md) | [3.0](/filings/0001376474-26-000059.md) | [4.2 d](/filings/0001376474-26-000348.md) | [3.8](/filings/0001376474-26-000514.md) | [3.7](/filings/0001376474-26-000664.md) | [3.7](/filings/0001376474-26-000059.md) | [4.7 d](/filings/0001376474-26-000348.md) | [7.3](/filings/0001376474-26-000514.md) | [3.2](/filings/0001376474-26-000664.md) |
| Income tax | $m | [0.8](/filings/0001376474-25-000101.md) | [0.8 d](/filings/0001376474-25-000437.md) | [0.8](/filings/0001376474-25-000658.md) | [0.8](/filings/0001376474-25-000857.md) | [0.5](/filings/0001376474-26-000059.md) | [0.8 d](/filings/0001376474-26-000348.md) | [0.7](/filings/0001376474-26-000514.md) | [0.8](/filings/0001376474-26-000664.md) | [0.8](/filings/0001376474-26-000059.md) | [0.3 d](/filings/0001376474-26-000348.md) | [1.3](/filings/0001376474-26-000514.md) | [0.5](/filings/0001376474-26-000664.md) |
| Net income | $m | [4.2](/filings/0001376474-25-000101.md) | [3.8 d](/filings/0001376474-25-000437.md) | [4.1](/filings/0001376474-26-000059.md) | [4.0](/filings/0001376474-26-000059.md) | [3.0](/filings/0001376474-26-000059.md) | [3.9 d](/filings/0001376474-26-000348.md) | [3.6](/filings/0001376474-26-000664.md) | [3.3](/filings/0001376474-26-000664.md) | [3.4](/filings/0001376474-26-000059.md) | [4.9 d](/filings/0001376474-26-000348.md) | [6.4](/filings/0001376474-26-000664.md) | [3.2](/filings/0001376474-26-000664.md) |
| Diluted EPS | $ per share | [0.87](/filings/0001376474-25-000101.md) | not reported | [0.85](/filings/0001376474-25-000658.md) | [0.83](/filings/0001376474-25-000857.md) | [0.63](/filings/0001376474-26-000059.md) | not reported | [0.74](/filings/0001376474-26-000514.md) | [0.68](/filings/0001376474-26-000664.md) | [0.70](/filings/0001376474-26-000059.md) | not reported | [1.32](/filings/0001376474-26-000514.md) | [0.65](/filings/0001376474-26-000664.md) |
| Basic EPS | $ per share | [0.87](/filings/0001376474-25-000101.md) | not reported | [0.85](/filings/0001376474-25-000658.md) | [0.83](/filings/0001376474-25-000857.md) | [0.63](/filings/0001376474-26-000059.md) | not reported | [0.74](/filings/0001376474-26-000514.md) | [0.68](/filings/0001376474-26-000664.md) | [0.70](/filings/0001376474-26-000059.md) | not reported | [1.32](/filings/0001376474-26-000514.md) | [0.66](/filings/0001376474-26-000664.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | Q2 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.7](/filings/0001376474-24-000040.md) | [10.3](/filings/0001376474-25-000437.md) | [6.0](/filings/0001376474-24-000323.md) | [3.1](/filings/0001376474-24-000614.md) | [5.5](/filings/0001376474-25-000101.md) | [8.0](/filings/0001376474-26-000348.md) | [3.2](/filings/0001376474-25-000658.md) | [5.1](/filings/0001376474-25-000857.md) | [3.4](/filings/0001376474-26-000059.md) | [1.7](/filings/0001376474-26-000664.md) | [2.9](/filings/0001376474-26-000514.md) | [4.0](/filings/0001376474-26-000664.md) |
| Current assets | $m | [29.2](/filings/0001376474-24-000040.md) | [33.2](/filings/0001376474-25-000437.md) | [31.5](/filings/0001376474-24-000323.md) | [33.8](/filings/0001376474-24-000614.md) | [30.3](/filings/0001376474-25-000101.md) | [33.2](/filings/0001376474-26-000348.md) | [26.2](/filings/0001376474-25-000658.md) | [28.8](/filings/0001376474-25-000857.md) | [31.1](/filings/0001376474-26-000059.md) | [32.2](/filings/0001376474-26-000664.md) | [35.7](/filings/0001376474-26-000514.md) | [35.1](/filings/0001376474-26-000664.md) |
| Total assets | $m | [67.6](/filings/0001376474-24-000040.md) | [66.8](/filings/0001376474-25-000437.md) | [66.7](/filings/0001376474-24-000323.md) | [65.9](/filings/0001376474-24-000614.md) | [64.6](/filings/0001376474-25-000101.md) | [64.3](/filings/0001376474-26-000348.md) | [63.6](/filings/0001376474-25-000658.md) | [61.5](/filings/0001376474-25-000857.md) | [60.0](/filings/0001376474-26-000059.md) | [60.4](/filings/0001376474-26-000664.md) | [62.1](/filings/0001376474-26-000514.md) | [59.9](/filings/0001376474-26-000664.md) |
| Current liabilities | $m | [0.8](/filings/0001376474-24-000040.md) | [1.0](/filings/0001376474-25-000437.md) | [1.7](/filings/0001376474-24-000323.md) | [0.9](/filings/0001376474-24-000614.md) | [0.8](/filings/0001376474-25-000101.md) | [1.2](/filings/0001376474-26-000348.md) | [1.6](/filings/0001376474-25-000658.md) | [1.0](/filings/0001376474-25-000857.md) | [0.9](/filings/0001376474-26-000059.md) | [1.1](/filings/0001376474-26-000664.md) | [1.5](/filings/0001376474-26-000514.md) | [1.2](/filings/0001376474-26-000664.md) |
| Total liabilities | $m | [1.0](/filings/0001376474-24-000040.md) | [1.2](/filings/0001376474-25-000437.md) | [1.8](/filings/0001376474-24-000323.md) | [1.0](/filings/0001376474-24-000614.md) | [1.6](/filings/0001376474-25-000101.md) | [2.0](/filings/0001376474-26-000348.md) | [2.5](/filings/0001376474-25-000658.md) | [1.8](/filings/0001376474-25-000857.md) | [1.7](/filings/0001376474-26-000059.md) | [2.1](/filings/0001376474-26-000664.md) | [2.3](/filings/0001376474-26-000514.md) | [1.9](/filings/0001376474-26-000664.md) |
| Shareholders' equity | $m | [66.6](/filings/0001376474-24-000040.md) | [65.6](/filings/0001376474-25-000437.md) | [64.9](/filings/0001376474-24-000323.md) | [64.9](/filings/0001376474-24-000614.md) | [63.0](/filings/0001376474-25-000101.md) | [62.3](/filings/0001376474-26-000664.md) | [61.1](/filings/0001376474-26-000664.md) | [59.7](/filings/0001376474-26-000664.md) | [58.3](/filings/0001376474-26-000059.md) | [58.2](/filings/0001376474-26-000664.md) | [59.8](/filings/0001376474-26-000664.md) | [58.0](/filings/0001376474-26-000664.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | Q2 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.7 d](/filings/0001376474-25-000101.md) | [3.1 d](/filings/0001376474-25-000437.md) | [5.9](/filings/0001376474-25-000658.md) | [2.1 d](/filings/0001376474-25-000857.md) | [3.8 d](/filings/0001376474-26-000059.md) | [2.5 d](/filings/0001376474-26-000348.md) | [5.2](/filings/0001376474-26-000514.md) | [2.8 d](/filings/0001376474-26-000664.md) | [4.2 d](/filings/0001376474-26-000059.md) | [4.5 d](/filings/0001376474-26-000348.md) | [5.3](/filings/0001376474-26-000514.md) | [5.8 d](/filings/0001376474-26-000664.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001376474-25-000101.md) | [0.0 d](/filings/0001376474-25-000437.md) | [0.9](/filings/0001376474-25-000658.md) | [0.2 d](/filings/0001376474-25-000857.md) | [10.2 d](/filings/0001376474-26-000059.md) | [(10.0) d](/filings/0001376474-26-000348.md) | [10.1](/filings/0001376474-26-000514.md) | [(9.0) d](/filings/0001376474-26-000664.md) | [9.0 d](/filings/0001376474-26-000059.md) | [(7.9) d](/filings/0001376474-26-000348.md) | [4.2](/filings/0001376474-26-000514.md) | [(4.1) d](/filings/0001376474-26-000664.md) |
| Dividends paid | $m | [4.8 d](/filings/0001376474-25-000101.md) | [4.8 d](/filings/0001376474-25-000437.md) | [4.8](/filings/0001376474-25-000658.md) | [4.8 d](/filings/0001376474-25-000857.md) | [4.8 d](/filings/0001376474-26-000059.md) | [4.8 d](/filings/0001376474-26-000348.md) | [4.8](/filings/0001376474-26-000514.md) | [4.8 d](/filings/0001376474-26-000664.md) | [4.8 d](/filings/0001376474-26-000059.md) | [4.8 d](/filings/0001376474-26-000348.md) | [4.8](/filings/0001376474-26-000514.md) | [4.8 d](/filings/0001376474-26-000664.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001376474-26-000664.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends, us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) | Q2 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,832](/filings/0001376474-24-000040.md) | [4,841](/filings/0001376474-24-000323.md) | [4,841](/filings/0001376474-24-000614.md) | [4,837](/filings/0001376474-25-000101.md) | [4,839](/filings/0001376474-25-000658.md) | [4,839](/filings/0001376474-25-000857.md) | [4,839](/filings/0001376474-26-000059.md) | [4,839](/filings/0001376474-26-000514.md) | [4,839](/filings/0001376474-26-000664.md) | [4,839](/filings/0001376474-26-000059.md) | [4,846](/filings/0001376474-26-000514.md) | [4,851](/filings/0001376474-26-000664.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,844,079 at 2026-09-30, from the cover of the [10-Q filed 2026-10-21](/filings/0001376474-26-000664.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.